



OMB No. 0651-0011

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

| | | | |
|------------------|-------------------|------------|------------|
| Atty. Docket No. | 08201.0027-00000 | Appln. No. | 10/077,137 |
| Applicant | BROWNING et al. | | |
| Filing Date | February 15, 2002 | Group: | 1633 |

U.S. PATENT DOCUMENTS

| Examiner Initial* | Document Number | Issue Date | Name | Class | Sub Class | Filing Date If Appropriate |
|-------------------|-----------------|------------|-------------|-------|-----------|----------------------------|
| PAO | 5,969,102 | 10/19/1999 | Bram et al. | 530 | 350 | |
| | 6,297,367 | 10/02/2001 | Tribouley | 536 | 23.5 | |
| | 6,316,222 | 11/13/2001 | Bram et al. | 435 | 69.1 | |
| | 6,475,986 | 11/05/2002 | Aggarwal | 514 | 12 | |
| ✓ | 6,541,224 | 04/01/2003 | Yu et al. | 435 | 69.5 | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | Document Number | Publication Date | Country | Class | Sub Class | Translation Yes or No |
|-----|-----------------|------------------|---------|-------|-----------|-----------------------|
| PAO | WO 00/26244 | 05/11/2000 | PCT | C07K | 14/00 | |
| PAO | WO 00/39295 | 07/06/2000 | PCT | C12N | 15/12 | |
| PAO | WO 00/40716 | 07/13/2000 | PCT | C12N | 15/11 | |
| PAO | WO 00/50633 | 08/31/2000 | PCT | C12Q | 1/00 | |
| PAO | WO 00/58362 | 10/05/2000 | PCT | C07K | 16/00 | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|-----|--|
| PAO | Hahne et al., "APRIL, a New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth," <i>J. Exp. Med.</i> 188:1185-1190 (1998) |
| PAO | Kashii, Y. et al., "CONSTITUTIVE EXPRESSION AND ROLE OF THE TNF FAMILY LIGANDS IN APOPTOTIC KILLING OF TUMOR CELLS BY HUMAN NK CELLS," <i>J. Immunol.</i> 163:5358-66 (1999) |
| PAO | Ward, P. and Mulligan, M. "BLOCKING OF ADHESION MOLECULES IN VIVO AS ANTI-INFLAMMATORY THERAPY," <i>Ther. Immunol.</i> 1:165-71 (1994) |
| PAO | Ware, C., "APRIL AND BAFF CONNECT AUTOIMMUNITY AND CANCER," <i>J. Exp. Med.</i> 192:F35-F37 (2000) |

| | | | |
|---------------|--|---|--------|
| Examiner | PATRICIA A. DUFFY | Date Considered | 3/5/05 |
| *Examiner: | Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |
| Form PTO 1449 | | Patent and Trademark Office - U.S. Department of Commerce | |



OMB No. 0651-0011

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

| | | | |
|------------------|-------------------|------------|------------|
| Atty. Docket No. | 08201.0027-00000 | Appln. No. | 10/077,137 |
| Applicant | BROWNING et al. | | |
| Filing Date | February 15, 2002 | Group: | 1633 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------|------------------|---------|-------|-----------|-----------------------|
| | Document Number | Publication Date | Country | Class | Sub Class | Translation Yes or No |
| PAD | WO 01/24811 | 04/12/2001 | PCT | A61K | 38/17 | |
| PAD | WO 02/02641 | 01/10/2002 | PCT | C07K | 16/00 | |
| PAD | WO 02/18620 | 03/07/2002 | PCT | C12Q | | |
| PAD | WO 03/055979 | 07/10/2003 | PCT | C12Q | | |
| PAD | WO 97/33902 | 09/18/1997 | PCT | C07H | 21/02 | |
| PAD | WO 98/18921 | 05/07/1998 | PCT | C12N | 15/12 | |
| PAD | WO 98/27114 | 06/25/1998 | PCT | C07K | 14/00 | |
| PAD | WO 98/55620 | 12/10/1998 | PCT | C12N | 15/19 | |
| PAD | WO 98/55621 | 12/10/1998 | PCT | C12N | 15/19 | |
| PAD | WO 99/11791 | 03/11/1999 | PCT | C12N | 12/12 | |
| PAD | WO 99/33980 | 07/08/1999 | PCT | C12N | 15/12 | |
| PAD | EP 0 869 180 A1 | 10/07/1998 | EPC | C12N | 15/19 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|--|---|
| PAD | von Bulow & Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily," <i>Science</i> 278:138-141 (1997) |
| PAD | Xia et al., "TACI is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation," <i>J. Exp. Med.</i> 192:137-143 (2000) |
| PAD | Yu et al., "APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity," <i>Nature Immunol.</i> 1:252-256 (2000) |
| PAD | Published U.S. Patent Application No. 10/214,065, filed August 7, 2002; Publication No. US 2003-0023038-A1, published January 30, 2003 |

| | | | |
|---------------|--|-----------------|--------|
| Examiner | PATRICIA A. DUFFY | Date Considered | 3/5/05 |
| *Examiner: | Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |
| Form PTO 1449 | Patent and Trademark Office - U.S. Department of Commerce | | |



OMB No. 0651-0011

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

| | | | |
|------------------|-------------------|------------|------------|
| Atty. Docket No. | 08201.0027-00000 | Appln. No. | 10/077,137 |
| Applicant | BROWNING et al. | | |
| Filing Date | February 15, 2002 | Group: | 1633 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | |
|--|---|
| PAD | Published U.S. Patent Application No. 10/380,703, filed March 17, 2003, Publication No. US-2004-0072188-A1, published April 15, 2004. |
| PAD | Published U.S. Patent Application No. 09/911,777, filed July 21, 2001; Publication No. US-2002-0037852-A1, published March 28, 2002 |
| PAD | Published U.S. Patent Application No. 10/115,192, filed April 2, 2002; Publication No. US-2003-0082175-A1, published May 1, 2003 |
| PAD | Published U.S. Patent Application No. 10/077,438, filed February 15, 2002; Publication No. US-2002-0165156-A1, published November 7, 2002 |
| PAD | Published U.S. Patent Application No. 10/258,368, filed June 23, 2003; Publication No. US-2004-0013674-A1, published January 22, 2004 |

| | | | |
|---------------|--|---|--------|
| Examiner | PATRICIA A. DUFFY | Date Considered | 3/5/05 |
| *Examiner: | Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | |
| Form PTO 1449 | | Patent and Trademark Office - U.S. Department of Commerce | |

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

| | |
|-------------------------------|-------------------|
| Application Number | 10/077,137 |
| Filing Date | 2/15/2002 |
| First Named Inventor | Browning, Jeffrey |
| Group Art Unit | 1633 |
| Examiner Name | TBD |
| Attorney Docket Number | A080 US |

Sheet 1 of 2

| | |
|------------------------|---------|
| Attorney Docket Number | A080 US |
|------------------------|---------|

[illegible]

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900
RECEIVED

NOV 20 2002

TECH CENTER 1600/2800

[illegible]

copy not
provided

PATRICIA A-DUFF

Considered

3/5/45


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/077,137 |
| Filing Date | 2/15/2002 |
| First Named Inventor | Browning, Jeffrey |
| Group Art Unit | 1633 |
| Examiner Name | TBD |
| Attorney Docket Number | A080 US |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------------------|-----------------------|---|----------------|
| PAO | CA | Gras et al., "BCMAp: an Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes", International Immunology, Vol. 7, No. 7, 1995, pgs. 1093-1106. | |
| PAO | CB | Gross et al., "TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease", Nature, Vol. 404, April 27 2000, pgs. 995-999. | |
| PAO | CC | Kwon et al., "Functions of Newly Identified Members of the Tumor Necrosis Factor Receptor/Ligand Superfamilies in Lymphocytes", Current Opinion in Immunology, 1999, pgs. 340-345. | |
| PAO | CD | Laabi et al., "A New Gene, BCM, on Chromosome 16 is Fused to the Interleukin 2 Gene by a (q26;p13) Translocation in a Malignant T Cell Lymphoma", The EMBO Journal, Vol. 11, No. 11, 1992, pgs. 3897-3904. | |
| PAO | CE | Laabi et al., "The BCMA Gene, Preferentially expressed during B Lymphoid Maturation, is Bidirectionally Transcribed", Nucleic Acids Research, Vol. 22, No. 7, 1994, pgs. 1147-1154. | |
| PAO | CF | Maldry et al., "The Characterization of Murine BCMA Gene Defines it as a New Member of the Tumor Necrosis Factor Receptor Superfamily", International Immunology, Vol. 10, No. 11, 1998, pgs. 1693-1702. | |
| PAO | CG | Pitti et al., "Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer", Nature, Vol. 396, December 17 1998, pgs. 699-703. | |
| PAO | CH | Schneider et al., "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth", J. Exp. Med., Vol. 189, No. 11, June 7 1999, pgs. 1747-1756. | |
| PAO | CI | Thompson et al., "BAFF Interacts with the Orphan Receptor, BCMA", Scandinavian Journal of Immunology, Vol. 51 (supplement 1), 2000, pg. 65. | |
| PAO | CJ | Thompson et al., "BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population", J. Exp. Med., Vol. 192, No. 1, July 3, 2000, pgs. 129-135. | |
| | | | |

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

| | | | |
|--------------------|-------------------------|-----------------|---------------|
| Examiner Signature | <u>DARILIA A. DUFFY</u> | Date Considered | <u>3/5/05</u> |
|--------------------|-------------------------|-----------------|---------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[X] Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

PM U.S. Patent Application No. 10/077,438, by Browning et al., filed February 15, 2002,
Docket No.: A080 USCIP

PM U.S. Patent Application No. 10/115,192, by Schneider et al., filed April 2, 2002, Docket
No.: A083 US

PM U.S. Patent Application No. 09/911,777, by Browning et al., filed July 24, 2001, Docket
No.: A070 US

Examiner

Date

Patricia A. Dwyer

3/5/05

- [X] A copy of each above-cited application, including the current claims, is enclosed.
- [] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- [] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [] Please charge Deposit Account 02-2327 in the amount of \$[]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 02-2327.

Respectfully submitted,

Date: 11/14/02

Timothy P. Linkkila

Timothy P. Linkkila
Reg. No. 40,702
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-3795 (Direct)
(617) 679-2838 (Facsimile)